SCHEMBL5025294

SCHEMBL5025294

O=C(NOC(F)(F)c1ccccn1)c1cccc2oc3ccc(C(F)(F)F)cc3c12

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TLR7 Q9NYK1 4/20 0.39
CETP P11597 6/20 0.38
SORT1 Q99523 1/20 0.36
POLB P06746 2/20 0.36
MEN1 O00255 1/20 0.36
MAPT P10636 1/20 0.36
KMT2A Q03164 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
TBK1 Q9UHD2 1/20 0.36
CSNK2A2 P19784 1/20 0.35
CSNK2B P67870 1/20 0.35
CSNK2A1 P68400 1/20 0.35
CSNK2A3 Q8NEV1 1/20 0.35
BRAF P15056 2/20 0.35
RAF1 P04049 1/20 0.35
PDGFRB P09619 1/20 0.35
PDGFRA P16234 1/20 0.35
KDR P35968 1/20 0.35
LMNA P02545 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5022681 0.73 ALDH1A1 (0.40) POLBMEN1MAPTKMT2ANPSR1
SCHEMBL5025291 0.72 POLQ (0.37) TLR7SORT1POLBMEN1MAPT
SCHEMBL5619680 0.71 MAPT (0.39) MAPTCSNK2A2CSNK2BCSNK2A1CSNK2A3
SCHEMBL6494766 0.69 PDE4D (0.34) POLBMEN1MAPTKMT2A
SCHEMBL5016434 0.66 PDE4D (0.49) SORT1MEN1MAPTKMT2A
SCHEMBL5618150 0.61 SMN1; SMN2 (0.36) MAPT
SCHEMBL6238717 0.61 ALDH1A1 (0.53) MEN1MAPTKMT2ATBK1LMNA
SCHEMBL2515353 0.61 MAOA (0.60) POLBMEN1MAPTKMT2ANPSR1
SCHEMBL11425148 0.61 HIF1A (0.44) MEN1MAPTKMT2A
SCHEMBL22044994 0.60 EPHX2 (0.47) TBK1CSNK2A2CSNK2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080146810-A1 NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM GLENMARK PHARMACEUTICALS S.A. (CH) 2008-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146810-A1 NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM LTC4S, TSLP, GPR119 TLR7 325/4885CETP 353/4885SORT1 2494/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.